Single-dose new insulin glargine 300U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes

Diabetes, Obesity and Metabolism

Volumn 17, Issue 3, 2015, Pages 254-260

  Shiramoto, M ^a   Eto, T ^a   Irie, S ^a   Fukuzaki, A ^b   Teichert, L ^c   Tillner, J ^c   Takahashi, Y ^b   Koyama, M ^b   Dahmen, R ^c   Heise, T ^d   Becker, R H A ^c  

^a Medical Co LTA Clinical Pharmacology Center   (Japan)

^b Sanofi KK   (Japan)

^c SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^d Profil   (Germany)

Author keywords

Insulin analogues; Pharmacodynamics; Pharmacokinetics; Type 1 diabetes

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN GLARGINE; INSULIN GLARGINE 100; INSULIN GLARGINE 300; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; LONG ACTING INSULIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIDIABETIC ACTIVITY; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; EUROPEAN; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GLUCOSE REGULATION SYSTEM; GLUCOSE UTILIZATION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; JAPANESE (PEOPLE); MALE; MULTIPLE DRUG DOSE; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; ADOLESCENT; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CAUCASIAN; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; GLUCOSE CLAMP TECHNIQUE; METABOLISM; MIDDLE AGED; PROCEDURES; SUBCUTANEOUS DRUG ADMINISTRATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GLUCOSE CLAMP TECHNIQUE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, SUBCUTANEOUS; INSULIN GLARGINE; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84961289782     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12415     Document Type: Article

References (15)

1. Yamamoto-Honda R, Takahashi Y, Yoshida Y et al. Use of insulin glargine in Japanese patients with type 1 diabetes. Intern Med 2007; 46: 937-943.
2. Pieber TR, Eugène-Jolchine I, Derobert E. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. Diabetes Care 2000; 23: 157-162.
3. Jax T, Heise H, Dahmen R et al. New insulin glargine formulation has a flat and prolonged steady state profile in subjects with type 1 diabetes. Diabetologia 2013; 56(Suppl. 1): S414.
4. Tillner J, Bergmann K, Teichert L, Dahmen R, Heise T, Becker RHA. Euglycaemic single dose clamp profile of new insulin glargine formulation in subjects with type 1 diabetes is flat and prolonged. Diabetologia 2013; 56(Suppl. 1): S415.
5. Seino Y, Nanjo K, Tajima N et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetol Int 2010; 1: 2-20.
6. The Expert Committee On The Diagnosis And Classification Of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1998; 21: S5-S19.
7. Kashiwagi A, Kasuga M, Araki E et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Investig 2012; 3: 39-40.
8. Steinstraesser A, Schmidt R, Bergmann K, Dahmen R, Becker RH. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml. Diabetes Obes Metab 2014; 16: 873-876.
9. Cochran E, Musso C, Gorden P. The use of U-500 in patients with extreme insulin resistance. Diabetes Care 2005; 28: 1240-1244.
10. Riddle MC, Bolli GB, Zieman M, Meuhlen-Bartmer I, Bizet F, Home PD. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care 2014; 37: 2755-2762.
11. Yki-Järvinen H, Bergenstal RM, Ziemen M et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care 2014; 37: 3235-3243.
12. Bolli GB, Riddle MC, Bergenstal B et al. New insulin glargine 300 U/mL: glycemic control and hypoglycemia in insulin naïve people with T2DM (EDITION 3) (Abstract). Diabetes 2014; 63(Suppl. 1): A19.
13. Home PD, Bergenstal B, Riddle MC et al. Glycemic control and hypoglycemia with new insulin glargine 300 U/mL in people with T1DM (EDITION 4) (Abstract). Diabetes 2014; 63(Suppl. 1A): LB19.
14. Matsuhisa M, Koyama M, Cheng XN, Shimizu S, Hirose T. New insulin glargine 300 U/mL: glycemic control and hypoglycemia in Japanese people with T1DM (EDITION JP 1) (Abstract). Diabetes 2014; 63(Suppl. 1A): LB22.
15. Terauchi Y, Koyama M, Cheng XN, Shimizu S, Hirose T. Glycemic control and hypoglycemia in Japanese people with T2DM receiving new insulin glargine 300 U/mLin combination with OADs (EDITION JP 2) (Abstract). Diabetes 2014; 63(Suppl. 1A): LB24.